Hyperuricemia and gout. Classification, complications and management.
D000208:Acute Disease; D000493:Allopurinol / Q000627:therapeutic use; D001168:Arthritis / Q000188:drug therapy / Q000378:metabolism; D001241:Aspirin / Q000009:adverse effects; D003078:Colchicine / Q000627:therapeutic use; D003327:Coronary Disease / Q000209:etiology; D004232:Diuretics / Q000009:adverse effects; D006073:Gout / Q000145:classification / Q000175:diagnosis* / Q000188:drug therapy; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000172:deficiency; D007213:Indomethacin / Q000627:therapeutic use; D007668:Kidney / Q000502:physiology; D007669:Kidney Calculi / Q000209:etiology; D007674:Kidney Diseases / Q000209:etiology; D007855:Lead Poisoning / Q000150:complications; D008232:Lymphoproliferative Disorders / Q000150:complications; D009196:Myeloproliferative Disorders / Q000150:complications; D010653:Phenylbutazone / Q000627:therapeutic use; D010974:Platelet Aggregation; D011339:Probenecid / Q000627:therapeutic use; D011686:Purine-Pyrimidine Metabolism, Inborn Errors / Q000150:complications; D011718:Pyrazinamide / Q000009:adverse effects; D012268:Ribose-Phosphate Pyrophosphokinase / Q000172:deficiency / Q000378:metabolism; D014527:Uric Acid / Q000097:blood* / Q000378:metabolism / Q000652:urine; D014528:Uricosuric Agents / Q000627:therapeutic use
D004232:Diuretics; D014528:Uricosuric Agents; D014527:Uric Acid; D011718:Pyrazinamide; D000493:Allopurinol; D007041:Hypoxanthine Phosphoribosyltransferase; D012268:Ribose-Phosphate Pyrophosphokinase; D010653:Phenylbutazone; D011339:Probenecid; D001241:Aspirin; D003078:Colchicine; D007213:Indomethacin